Georg-august-universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin

Lifearc

Synaptic Systems Gesellschaft Für Neurobiologische Forschung, Entwicklung Und Produktion Mbh

Thomas Bayer

Oliver Wirths

David Matthews

Alex Brown

Mark Carr

Preeti Bakrania

Henrik Martens

Christian Erck

Gareth Hall

Chido Mpamhanga

Sarah Davies

The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).

Humanised anti-n-truncated amyloid β monoclonal antibody

The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric A&#x3b2; oligomers, wherein said antibody molecule does not bind human monomeric A&#x3b2; 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.

Conformational-specific antibodies against A[&#x3b2;] oligomers

The present invention describes a novel transgenic mouse model for the common sporadic form of Alzheimer's disease. More particularly, the invention relates to a nucleotide sequence encoding A&#x3b2; 4-42 in functional linkage with at least a promoter, signal peptide sequence and a polyadenylation signal sequence, a cell and a transgenic non-human animal comprising said nucleotide sequence, and their respective use in screening methods.

Transgenic mouse model expressing amyloid &#x3b2; 4-42 peptide

The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A&#x3b2; starting with pyroglutamate (A&#x3b2;&#x3c1;E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A&#x3b2; oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said A&#x3b2;&#x3c1;E oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of A&#x3b2; oligomers in a subject.

Monoclonal antibodies targeting amyloid beta oligomers

Growing community of inventors

Göttingen, Germany

Thomas Bayer